A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma
- Conditions
- Advanced Solid Malignancies, Malignant Lymphoma
- Registration Number
- JPRN-jRCT2080221904
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Patients who have signed this Written Informed Consent Form after a full explanation about the participation in this study
- Patients aged 18 years or older Patients diagnosed with a solid malignant tumour or malignant lymphoma that is refractory to standard therapies or for which no standard therapies exist
- Patients with good physical conditions (you can walk and can look after yourself) within the last 2 weeks.
- Patients who have at least one lesion that can be accurately assessed
- Patients who have recently received or are receiving prohibited medications or treatments
- Patients who have any unresolved side effects of previous treatments
- Patients who have spinal cord compression or brain metastases
- Patients who have severe systemic diseases (e.g., uncontrolled hypertension, hepatitis B, hepatitis C and human immunodeficiency virus [HIV] infection)
- Patients with significant abnormal ECG findings
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method